Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (5362)	9/21/1998 6:19:00 PM
From: billkirn	of 6136

The wind is firmly at our backs. So much encouraging news that seems to indicate a long and prosperous life for Viracept. Over the last month, information from many fronts has reduced the risk and increased the earnings prospects for Agouron. Finally the overwhelming evidence supports Viracept as the major component in AIDS treatment. It works in almost all combinations and hopefully with Sustiva (1 dose), Viracept (2 dose) per day and a favorable combo resistance and side stuff profiles could replace Crix completely over the next few years. Only good news for awhile, isn't this nice! Bill

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next